IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation

Geok Choo Sim, Chengwen Liu, Ena Wang, Hui Liu, Caitlin Creasy, Zhimin Dai, Willem W. Overwijk, Jason Roszik, Francesco Marincola, Patrick Hwu, Elizabeth Grimm, Laszlo Radvanyi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Clinical responses to high-dose IL2 therapy are limited due to selective expansion of CD4+CD25+Foxp3+ T-regulatory cells (Treg), especially ICOS+ Tregs, rather than natural killer (NK) cells and effector T cells. These ICOS+ Tregs are highly suppressive and constitutively express high levels of IL2Rα (CD25) and CD39. Here, we characterized the effect of a mutant form of IL2 (F42K), which preferentially binds to the lower affinity IL2Rβγ with reduced binding to CD25, on Tregs, effector NK cells, and T-cell subsets. Unlike wild-type (WT) IL2, F42K did not efficiently induce the expansion of highly suppressive ICOS+ Tregs in peripheral blood mononuclear cells (PBMC) from healthy controls and melanoma patients. Instead, it promoted the expansion of CD16+CD56+ NK cells and CD56hiCD16- NK cell subsets in both short- and long-term cultures, with enhanced Bcl-2 expression. Stimulation of PBMCs with F42K induced expression of more NK cell activation molecules, such as NKp30, NKp44, DNAM-1, NKG2D, 4-1BB/CD137, and Tim-3, than WT IL2. F42K induced greater upregulation of TRAIL, and NK-mediated cytolytic activity was increased against both autologous and HLA-mismatched melanoma cells compared with WT IL2. Gene expression analysis revealed distinct gene expression profiles stimulated by F42K, WT IL2, and IL15. F42K therapy in vivo also induced a dramatic reduction in the expansion of ICOS+ Tregs, promoted NK cell expansion, and inhibited melanoma tumor growth more efficiently than WT IL2 and more effectively than anti-CTLA-4. Our findings suggest that F42K could be a potential substitute for WT IL2 as a cytokine therapy for cancer.

Original languageEnglish
Pages (from-to)983-994
Number of pages12
JournalCancer immunology research
Volume4
Issue number11
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

Regulatory T-Lymphocytes
Natural Killer Cells
Interleukin-2
Melanoma
Interleukin-15
T-Lymphocyte Subsets
Transcriptome
Blood Cells
Neoplasms
Up-Regulation
Therapeutics
Cytokines
T-Lymphocytes
Gene Expression
Growth

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation. / Sim, Geok Choo; Liu, Chengwen; Wang, Ena; Liu, Hui; Creasy, Caitlin; Dai, Zhimin; Overwijk, Willem W.; Roszik, Jason; Marincola, Francesco; Hwu, Patrick; Grimm, Elizabeth; Radvanyi, Laszlo.

In: Cancer immunology research, Vol. 4, No. 11, 01.11.2016, p. 983-994.

Research output: Contribution to journalArticle

Sim, GC, Liu, C, Wang, E, Liu, H, Creasy, C, Dai, Z, Overwijk, WW, Roszik, J, Marincola, F, Hwu, P, Grimm, E & Radvanyi, L 2016, 'IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation', Cancer immunology research, vol. 4, no. 11, pp. 983-994. https://doi.org/10.1158/2326-6066.CIR-15-0195
Sim, Geok Choo ; Liu, Chengwen ; Wang, Ena ; Liu, Hui ; Creasy, Caitlin ; Dai, Zhimin ; Overwijk, Willem W. ; Roszik, Jason ; Marincola, Francesco ; Hwu, Patrick ; Grimm, Elizabeth ; Radvanyi, Laszlo. / IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation. In: Cancer immunology research. 2016 ; Vol. 4, No. 11. pp. 983-994.
@article{3be08cbac3d941cea087bba0107bbe95,
title = "IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation",
abstract = "Clinical responses to high-dose IL2 therapy are limited due to selective expansion of CD4+CD25+Foxp3+ T-regulatory cells (Treg), especially ICOS+ Tregs, rather than natural killer (NK) cells and effector T cells. These ICOS+ Tregs are highly suppressive and constitutively express high levels of IL2Rα (CD25) and CD39. Here, we characterized the effect of a mutant form of IL2 (F42K), which preferentially binds to the lower affinity IL2Rβγ with reduced binding to CD25, on Tregs, effector NK cells, and T-cell subsets. Unlike wild-type (WT) IL2, F42K did not efficiently induce the expansion of highly suppressive ICOS+ Tregs in peripheral blood mononuclear cells (PBMC) from healthy controls and melanoma patients. Instead, it promoted the expansion of CD16+CD56+ NK cells and CD56hiCD16- NK cell subsets in both short- and long-term cultures, with enhanced Bcl-2 expression. Stimulation of PBMCs with F42K induced expression of more NK cell activation molecules, such as NKp30, NKp44, DNAM-1, NKG2D, 4-1BB/CD137, and Tim-3, than WT IL2. F42K induced greater upregulation of TRAIL, and NK-mediated cytolytic activity was increased against both autologous and HLA-mismatched melanoma cells compared with WT IL2. Gene expression analysis revealed distinct gene expression profiles stimulated by F42K, WT IL2, and IL15. F42K therapy in vivo also induced a dramatic reduction in the expansion of ICOS+ Tregs, promoted NK cell expansion, and inhibited melanoma tumor growth more efficiently than WT IL2 and more effectively than anti-CTLA-4. Our findings suggest that F42K could be a potential substitute for WT IL2 as a cytokine therapy for cancer.",
author = "Sim, {Geok Choo} and Chengwen Liu and Ena Wang and Hui Liu and Caitlin Creasy and Zhimin Dai and Overwijk, {Willem W.} and Jason Roszik and Francesco Marincola and Patrick Hwu and Elizabeth Grimm and Laszlo Radvanyi",
year = "2016",
month = "11",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0195",
language = "English",
volume = "4",
pages = "983--994",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - IL2 variant circumvents ICOS+ regulatory T-cell expansion and promotes NK cell activation

AU - Sim, Geok Choo

AU - Liu, Chengwen

AU - Wang, Ena

AU - Liu, Hui

AU - Creasy, Caitlin

AU - Dai, Zhimin

AU - Overwijk, Willem W.

AU - Roszik, Jason

AU - Marincola, Francesco

AU - Hwu, Patrick

AU - Grimm, Elizabeth

AU - Radvanyi, Laszlo

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Clinical responses to high-dose IL2 therapy are limited due to selective expansion of CD4+CD25+Foxp3+ T-regulatory cells (Treg), especially ICOS+ Tregs, rather than natural killer (NK) cells and effector T cells. These ICOS+ Tregs are highly suppressive and constitutively express high levels of IL2Rα (CD25) and CD39. Here, we characterized the effect of a mutant form of IL2 (F42K), which preferentially binds to the lower affinity IL2Rβγ with reduced binding to CD25, on Tregs, effector NK cells, and T-cell subsets. Unlike wild-type (WT) IL2, F42K did not efficiently induce the expansion of highly suppressive ICOS+ Tregs in peripheral blood mononuclear cells (PBMC) from healthy controls and melanoma patients. Instead, it promoted the expansion of CD16+CD56+ NK cells and CD56hiCD16- NK cell subsets in both short- and long-term cultures, with enhanced Bcl-2 expression. Stimulation of PBMCs with F42K induced expression of more NK cell activation molecules, such as NKp30, NKp44, DNAM-1, NKG2D, 4-1BB/CD137, and Tim-3, than WT IL2. F42K induced greater upregulation of TRAIL, and NK-mediated cytolytic activity was increased against both autologous and HLA-mismatched melanoma cells compared with WT IL2. Gene expression analysis revealed distinct gene expression profiles stimulated by F42K, WT IL2, and IL15. F42K therapy in vivo also induced a dramatic reduction in the expansion of ICOS+ Tregs, promoted NK cell expansion, and inhibited melanoma tumor growth more efficiently than WT IL2 and more effectively than anti-CTLA-4. Our findings suggest that F42K could be a potential substitute for WT IL2 as a cytokine therapy for cancer.

AB - Clinical responses to high-dose IL2 therapy are limited due to selective expansion of CD4+CD25+Foxp3+ T-regulatory cells (Treg), especially ICOS+ Tregs, rather than natural killer (NK) cells and effector T cells. These ICOS+ Tregs are highly suppressive and constitutively express high levels of IL2Rα (CD25) and CD39. Here, we characterized the effect of a mutant form of IL2 (F42K), which preferentially binds to the lower affinity IL2Rβγ with reduced binding to CD25, on Tregs, effector NK cells, and T-cell subsets. Unlike wild-type (WT) IL2, F42K did not efficiently induce the expansion of highly suppressive ICOS+ Tregs in peripheral blood mononuclear cells (PBMC) from healthy controls and melanoma patients. Instead, it promoted the expansion of CD16+CD56+ NK cells and CD56hiCD16- NK cell subsets in both short- and long-term cultures, with enhanced Bcl-2 expression. Stimulation of PBMCs with F42K induced expression of more NK cell activation molecules, such as NKp30, NKp44, DNAM-1, NKG2D, 4-1BB/CD137, and Tim-3, than WT IL2. F42K induced greater upregulation of TRAIL, and NK-mediated cytolytic activity was increased against both autologous and HLA-mismatched melanoma cells compared with WT IL2. Gene expression analysis revealed distinct gene expression profiles stimulated by F42K, WT IL2, and IL15. F42K therapy in vivo also induced a dramatic reduction in the expansion of ICOS+ Tregs, promoted NK cell expansion, and inhibited melanoma tumor growth more efficiently than WT IL2 and more effectively than anti-CTLA-4. Our findings suggest that F42K could be a potential substitute for WT IL2 as a cytokine therapy for cancer.

UR - http://www.scopus.com/inward/record.url?scp=85016154548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016154548&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0195

DO - 10.1158/2326-6066.CIR-15-0195

M3 - Article

VL - 4

SP - 983

EP - 994

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 11

ER -